Welcome to our dedicated page for Propanc Biopharma news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Biopharma stock.
Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Propanc Biopharma (OTC Pink: PPCB) announced breakthrough findings on PRP, its novel cancer treatment, demonstrating its ability to suppress the TGF-β pathway in pancreatic cancer. Research by Mrs. Belén Toledo Cutillas revealed that PRP effectively reduced tumor growth factors and inhibited chemoresistant tumor cells. Chief Scientific Officer Dr. Julian Kenyon emphasized PRP's potential as a chemosensitizing agent, potentially improving treatment outcomes for resistant solid tumors. PRP, derived from pancreatic proenzymes, shows promise in targeting various cancers without the typical side effects of standard therapies.
Propanc Biopharma, Inc. (OTC Pink: PPCB) announced findings regarding its proenzyme therapy, PRP, which shows significant effects against chemoresistant pancreatic tumor cells. Research conducted by Mrs. Belén Toledo Cutillas at the University of Jaén indicates that PRP downregulates chemoresistant gene expression in treated cells. Chief Scientific Officer Dr. Julian Kenyon emphasized that PRP alters the tumor microenvironment and could enhance clinical outcomes for pancreatic cancer patients. PRP, a mixture of two proenzymes, aims to prevent tumor recurrence and metastasis in various cancers.